Is Moderna Still a Compelling Growth Play?
Moderna (NASDAQ: MRNA) has had a banner year in 2020. Thanks to the biotech's COVID-19 vaccine candidate mRNA-1273, the company's shares have gapped up by an eye-catching 400% this year.
The biotech's red-hot growth streak, though, may be nearing an end. BMO Capital analyst George Farmer, for instance, said earlier this week that he believes mRNA-1273's commercial potential is already priced into the company's valuation at this point.
Image source: Getty Images.
Source Fool.com
